Cargando…
Advances in the Study of Bioactive Nanoparticles for the Treatment of HCC and Its Postoperative Residual Cancer
Primary hepatocellular carcinoma (HCC, hepatocellular carcinoma) is the third leading cause of tumor death in the world and the second leading cause in China. The high recurrence rate at 5 years after surgery also seriously affects the long-term survival of HCC patients. For reasons such as poor liv...
Autores principales: | Li, Yanxu, Zou, Hao, Zheng, Zekun, Liu, Zhuoheng, Hu, Huiyuan, Wu, Wei, Wang, Tao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216871/ https://www.ncbi.nlm.nih.gov/pubmed/37250475 http://dx.doi.org/10.2147/IJN.S399146 |
Ejemplares similares
-
HCC: RNA-Sequencing in Cirrhosis
por: Wang, Haoyu, et al.
Publicado: (2023) -
Augmented EPR effect post IRFA to enhance the therapeutic efficacy of arsenic loaded ZIF-8 nanoparticles on residual HCC progression
por: Chen, Xuehua, et al.
Publicado: (2022) -
Correction to: Augmented EPR effect post IRFA to enhance the therapeutic efficacy of arsenic loaded ZIF-8 nanoparticles on residual HCC progression
por: Chen, Xuehua, et al.
Publicado: (2022) -
Advances in Immunotherapy for Hepatocellular Carcinoma (HCC)
por: Bicer, Fuat, et al.
Publicado: (2023) -
The Pre- and Postoperative FIB-4 Indexes Are Good Predictors to the Outcomes of HBV-Related HCC Patients after Resection
por: Tsai, Meng-Yun, et al.
Publicado: (2019)